Invivyd opened lower at $0.59, compared with its previous close of $0.60. In the last trading session, the stock traded between $0.55 and $0.60. It showed a downward intraday trend.
Return calculator
Time Period
An investment of $100 made 5 years ago in Invivyd is now worth
$ 11.66
Resulting in a loss of
$ 88.34 (88.34%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 3 Analysts
Buy
100%
Hold
0%
Sell
0%
Markets Today
Today's Change
$-0.04 (-6.06%)
Day High
$0.60
Day Low
$0.55
Day Open
$0.59
Prev Close
$0.60
Volume
23,96,062
1W Return
-10.78%
1M Return
-16.47%
3M Return
-18.29%
6M Return
-62.72%
1Y Return
-65.88%
Fundamentals
Market Cap ($ Mn)
166
PE Ratio
-
PB Ratio
1.57
PEG Ratio
-
ROE
-52.59%
ROCE
-52.10%
EPS (TTM)
$0.00
Investment Returns
1 Week
-10.78%
1 Month
-16.47%
3 Months
-18.29%
6 Months
-62.72%
9 Months
-65.03%
Financials
Quarterly
All values in $ Mn
11.3
Mar 25
11.8
Jun 25
13.1
Sep 25
17.2
Dec 25
13.7
Mar 26
14.3
Jun 26
Updates
21Oct
Invivyd presents preclinical data for measles antibody VMS063
Invivyd Inc. presented preclinical data for VMS063 at IDWeek 2026. VMS063 showed potent in vitro antiviral activity against contemporary measles variants. No FDA-approved treatments currently exist for measles. Invivyd plans to scale up production for clinical development starting in 2027. The U.S. faces record-breaking measles cases in 2026 with a significant immunity gap.
22 days ago
30Sep
Invivyd outlines accelerated approval path for COVID antibody
VYD2311 showed 56.5% adverse event rate vs 91.4% for mRNA vaccine over six days. Combination therapy increased neutralizing titers by approximately 2.5 times. Invivyd plans BLA submission under FDA Accelerated Approval Program based on LIBERTY and DECLARATION data.
1mo ago
8Sep
Invivyd to present at three September investor conferences
Invivyd CEO Marc W. Elia and management to attend three September investor conferences in New York. Fireside chats scheduled at Cantor Global Healthcare and H.C. Wainwright conferences. Live webcasts available on company website; meetings open via broker representatives.
2mo ago
1Sep
Invivyd appoints Marc Elia as CEO; expects VYD2311 data late Q3 2026
Marc W. Elia appointed CEO and continues as Chairman of Invivyd Inc. Top-line data from VYD2311 program expected around end of Q3 2026. Company plans BLA filing shortly after data release, targeting traditional or accelerated approval. Ajay Royan named Lead Independent Director; Ian Sheffield joins board.
2mo ago
7Jul
BTIG reiterates Buy rating on Invivyd, maintains $10 price target
BTIG analyst Thomas Shrader has reiterated a Buy rating for Invivyd, maintaining a price target of $10. The endorsement signals continued confidence in the company's market performance and valuation potential.
4mo ago
6Jul
FDA terminates Pemgarda EUA effective June 29, 2027
The FDA issued a notice of termination for the Pemgarda EUA, effective June 29, 2027, following an HHS announcement. Invivyd is engaging with regulators on next steps and aims to maintain access for vulnerable patients.
